531978 Sigma-AldrichATM Inhibitor, KU 60019 - CAS 925701-46-8 - Calbiochem
ATM kinase inhibitor, KU60019, is a cell permeable, potent inhibitor of ATM kinase inhibitor (IC₅₀ = 6.3 nM). Has 270 & 1600-fold higher selectivity over DNA-PK and ATR kinase.
More>> ATM kinase inhibitor, KU60019, is a cell permeable, potent inhibitor of ATM kinase inhibitor (IC₅₀ = 6.3 nM). Has 270 & 1600-fold higher selectivity over DNA-PK and ATR kinase. Less<<Synonyms: KU-60019, KU60019, Ataxia Telangiectasia Mutate Kinase Inhibitor
Recommended Products
Overview
Replacement Information |
---|
Key Specifications Table
CAS # | Empirical Formula |
---|---|
925701-46-8 | C₃₀H₃₃N₃O₅S |
Pricing & Availability
Catalog Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
5.31978.0001 |
|
Glass bottle | 10 mg |
|
— |
References | |
---|---|
References | Biddlestone-Thorpe, L., et al. 2013. Clin. Cancer Res. 19, 3189. Golding, S., et al. 2009. Mol. Cancer Ther. 8, 2894. |
Product Information | |
---|---|
CAS number | 925701-46-8 |
Form | Light beige solid |
Hill Formula | C₃₀H₃₃N₃O₅S |
Chemical formula | C₃₀H₃₃N₃O₅S |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | ATM |
Primary Target IC<sub>50</sub> | 6.3 nM |
Purity | ≥98% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalog Number | GTIN |
5.31978.0001 | 04055977287127 |
Documentation
ATM Inhibitor, KU 60019 - CAS 925701-46-8 - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Biddlestone-Thorpe, L., et al. 2013. Clin. Cancer Res. 19, 3189. Golding, S., et al. 2009. Mol. Cancer Ther. 8, 2894. |